Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.53 |
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 8/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.45 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.45 |
| ▸ | PRKACA | P17612 | 1/20 | 0.45 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.45 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.45 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.45 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.45 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.45 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.45 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | PRKX | P51817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1536379 | 0.84 | PARP1 (0.53) | PARP1GRM5CHEK1PIM1RPS6KA3 | |
| SCHEMBL31038353 | 0.84 | PARP1 (0.53) | PARP1GRM5CHEK1PIM1RPS6KA3 | |
| SCHEMBL23416324 | 0.80 | GAA (0.48) | PARP1GRM5ROCK1ROCK2PRKCD | |
| SCHEMBL23416343 | 0.79 | GRM5 (0.41) | PARP1GRM5CHEK1PIM1RPS6KA3 | |
| SCHEMBL24347857 | 0.78 | PARP1 (0.52) | PARP1GRM5ROCK1ROCK2PRKCD | |
| SCHEMBL17321356 | 0.78 | PARP1 (0.50) | PARP1GRM5CHEK1ROCK1ROCK2 | |
| SCHEMBL25151218 | 0.76 | PARP1 (0.53) | PARP1GRM5CHEK1ROCK1ROCK2 | |
| SCHEMBL1551818 | 0.76 | AHR (0.53) | PARP1GRM5CHEK1LMNAROCK1 | |
| SCHEMBL6005220 | 0.76 | PARP1 (0.53) | PARP1GRM5CHEK1ROCK1ROCK2 | |
| SCHEMBL1536304 | 0.76 | CHEK1 (0.61) | PARP1GRM5CHEK1ROCK1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114805204-A | Method for preparing 4-iodoisoquinoline-1 (2H) -ketone compound | 云南师范大学 | 2022-07-29 | — | — | CN | claimed |
| CN-111850631-A | High-gloss decorative rhodium-plated layer electroplating solution | 金川集团股份有限公司 | 2020-10-30 | — | — | CN | claimed |
| US-20040122223-A1 | Non-natural nucleotides and dinucleotides | CELLTECH R & D LIMITED (GB) | 2004-06-24 | — | — | US | claimed |
| EP-4739306-A2 | POLO-LIKE KINASE 1 INHIBITORS | Cervero Therapeutics, LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| WO-2024105364-A1 | HETEROCYCLIC INHIBITORS OF CDC-LIKE KINASES | CURADEV PHARMA LTD (GB) | 2024-05-23 | — | — | WO | disclosed |
| CN-114805204-B | Method for preparing 4-iodoisoquinoline-1 (2H) -ketone compound | 云南师范大学 | 2023-09-15 | — | — | CN | disclosed |
| US-20230226057-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF FIBROTIC DISEASE | TOLREMO THERAPEUTICS AG (CH) | 2023-07-20 | — | — | US | disclosed |
| EP-4198034-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Tuojie Biotech (Shanghai) Co., Ltd. (CN) | 2023-06-21 | — | — | EP | disclosed |
| WO-2023104111-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | NANJING ZENSHINE PHARMACEUTICALS CO., LTD. (CN) | 2023-06-15 | — | — | WO | disclosed |
| US-20230027295-A1 | FXIA INHIBITORS AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| CN-114805204-A | Method for preparing 4-iodoisoquinoline-1 (2H) -ketone compound | 云南师范大学 | 2022-07-29 | — | — | CN | disclosed |
| WO-2002062816-A1 | NON-NATURAL NUCLEOTIDES AND DINUCLEOTIDES | CELLTECH R & D LIMITED (GB) | 2002-08-15 | — | — | WO | disclosed |
| US-20020013310-A1 | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2002-01-31 | — | — | US | disclosed |
| EP-1086099-A4 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARM PROD INC (US) | 2002-01-02 | — | — | EP | disclosed |
| US-6281227-B1 | INHIBITORS OF THE ACTIVITY OF FACTOR XA. | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-08-28 | — | — | US | disclosed |
| EP-0944386-A4 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARM PROD INC (US) | 2001-04-11 | — | — | EP | disclosed |
| EP-1086099-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | Aventis Pharmaceuticals Products Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999062904-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| EP-0944386-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998025611-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027295-A1 | FXIA INHIBITORS AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | F11, TFPI, F7 | PARP1 1733/4885GRM5 4449/4885CHEK1 4878/4885 |
| US-20040122223-A1 | Non-natural nucleotides and dinucleotides | P2RY1, P2RY11, P2RY13 | PARP1 543/4885GRM5 2025/4885CHEK1 2444/4885 |
| US-20230226057-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF FIBROTIC DISEASE | CPT1A, SLC10A1, FGF1 | PARP1 4183/4885GRM5 3516/4885CHEK1 3801/4885 |
| US-20020013310-A1 | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | STS, ARSA, F12 | PARP1 3345/4885GRM5 3824/4885CHEK1 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.